Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2012. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary Shares by several executives on March 9, 2012, at a price of 1420 pence per share through the Company's ShareReward Plan. The transactions include both personal contributions and matching company contributions. Specific acquisitions include:
- Sir Andrew Witty: 8 shares (personal) and 8 shares (company match).
- Mr S Dingemans: 8 shares (personal) and 8 shares (company match).
- Mr S M Bicknell: 8 shares (personal) and 8 shares (company match).
- Mr E J Gray: 8 shares (personal) and 8 shares (company match).
- Mr D S Redfern: 8 shares (personal) and 8 shares (company match).
- Ms C Thomas: 8 shares (personal) and 8 shares (company match).
- Mr P C Thomson: 7 shares (personal) and 7 shares (company match).
- Dr P J T Vallance: 9 shares (personal) and 9 shares (company match).
- Mrs V A Whyte: 8 shares (personal) and 8 shares (company match).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of share transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the share price of 1420 pence per Ordinary Share as of March 9, 2012.
- Confirm the total number of shares acquired by each listed executive under the ShareReward Plan.
- Review the company's broader annual report (Form 20-F) for comprehensive financial performance data, as this filing contains none.